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ABSTRACT 
BACKGROUND 
Breast cancer is the second most common cancer among females in 
India with increasing mortality. Most of the patients presents to the hospital in 
advanced stage of the disease. Locally advanced breast carcinoma (LABC) 
includes stage IIb, IIIa, IIIb. Multi-disciplinary approach with Chemotherapy, 
Surgery, Radiotherapy and Hormone therapy is the main stay of treatment 
which improves the quality of life and prolongs disease free interval 
OBJECTIVE 
To find the age incidence, various presentations, response to neo 
adjuvant chemotherapy, various modalities and the disease free survival of 
patients with LABC. 
METHODS 
This Prospective study was conducted on the patients with Locally 
advanced breast carcinoma who attended surgical OPD in Surgery Department 
in Government Mohan Kumaramangalam Medical College Hospital, Salem. 
After complete evaluation, Neo-adjuvant Chemotherapy was given to 
downstage the tumour followed by Modified Radical Mastectomy. Adjuvant 
chemotherapy and radiotherapy was given to reduce further metastasis and 
prevent Loco-regional recurrence. 
 
OBSERVATION & RESULTS 
In my study, the highest age incidence for LABC is from 40-49  
years of age, predominantly in post-menopausal age group, TNM Stage III B is 
the common stage of LABC in this group of people. Most patients responded 
very well to Neo-adjuvant chemotherapy with minimal side-effects.  
Post-operative Chemotherapy, Radiotherapy reduces the overall local 
recurrence to 5% and systemic metastases to 7%. 
CONCLUSION 
This Multi-disciplinary approach therefore enhances the quality of life 
of the breast carcinoma patients by reducing the morbidity and improving the 
overall survival rate and disease free survival, when combined properly.  
KEY WORDS 
Breast Cancer, Neo-adjuvant chemotherapy, modified radical 
mastectomy, Radiotherapy.  
  
 
  
INTRODUCTION 
Breast cancer originates from the inner lining of lactiferous ducts or the 
lobules that supplies the duct9. Breast cancer is one of the slow growing 
tumours which render it suitable for screening programs. Though there are few 
exceptions which show aggressive growth. 
World-wide breast cancer accounts for about 22-23% of all cancers in 
women & about 13-14% cancer deaths in women10.  It is 100 times more 
common in women than men11  In India breast cancer stands next to cancer 
cervix and the incidence is in steady increase as equivalent to developed 
countries. 
Breast cancer should be detected in its early stage to improve the overall 
survival and disease free interval. The disease progresses from normality to 
hyperplasia, atypia, carcinoma in situ and finally to invasive carcinoma. 
Triple assessment of the patient, staging, imaging modalities and FNAC 
helps in differentiating early breast cancer from advanced cancer. The term 
locally advanced breast cancer (LABC)  
Includes STAGE IIB, IIIA, IIIB of Breast carcinoma   
♦ Large breast tumours (more than 5 cm in diameter) 
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♦ Cancers that involves the skin over the breast or the underlying 
muscles of the chest 
♦ Cancers that involve multiple local lymph nodes  
♦ Multi-disciplinary approach is the present approach for LABC, 
that involves :   
• Neo-adjuvant chemotherapy, 
• Surgery, 
• Adjuvant chemotherapy 
• Radiotherapy  
• With hormone therapy. 
Administration of systemic chemo/hormone therapy before surgery 
helps in reduction of tumour size to about 50 – 60 % along with preventing 
further systemic metastasis NACT (Neo-adjuvant chemotherapy) therefore 
enhances the quality of the breast carcinoma patients by reducing the morbidity 
and improving the overall survival rate and disease free survival, when 
combined properly with surgery and adjuvant therapy. 
New era of systemic therapy is based on ER/PR & HER2neu Status, 
which gives the edge in selecting the type of drugs that is to be administered. 
Metastatic workup is a must for LABC patients in deciding the 
treatment line and for follow-up and prognosis.  
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AIM OF THE STUDY 
This study was conducted on patients who were treated in Government 
Mohan Kumaramangalam Medical College Hospital, Salem for a period of 2 
years.  
  To find the age incidence of Locally Advanced Breast 
 Carcinoma (LABC). 
  To study the various presentations of LABC. To study the 
 responses to neo adjuvant chemotherapy in LABC patients. 
  To view the various modalities of management of LABC. 
  To find out the disease free survival of patients with LABC. 
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REVIEW OF LITERATURE 
A BRIEF HISTORY OF BREAST CANCER THERAPY 
Earliest known document on breast cancer is in the Smith Surgical 
Papyrus (3000–2500 B.C.)1 Few other historical references to breast cancer 
until the firstcentury. In De Medicina, Celsus Commented on the value of 
operations for early breast Cancer: “None of these may be removed but the 
cacoethes (early cancer), the more violent the operations are the more  angrier 
they grow”.2 
In the second century, Galen described his classical Clinical observation 
on breast tumour that resembling the animal - Crab. Just as the crab have legs 
on both sides of his body, so in this disease the veins extending out from the 
unnatural growth take the shape of a crab's legs. Often cured in its early stages, 
but after it has reached a large size, no one has cured it.3 Morgagni tried some 
early attempts at mastectomy and axillary dissection for breast cancer5 
In 1894, Halsted and Meyer started on radical mastectomy and complete 
dissection of axillary lymphnode levels I to III.4  
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In 1943, Haagensen and Stout described the grave signs of breast 
cancer, which included: 
(a)  Edema of the skin of the breast,  
(b)  Skin ulceration,  
(c)  Chest wall fixation,  
(d)  An axillary lymph node >2.5 cm in diameter, and  
(e)  Fixed axillary lymph nodes.  
Women with two or more signs had a 42-43% local recurrence rate and 
only a 2% 5-year disease-free survival rate.6 In 1948, Patey & Middlesex 
hospital advocated a modified radical mastectomy for the management of 
advanced operable breast cancer, showed that removal of thepectoralis minor 
muscle allowed access to and clearance of axillary lymph node levels I to III. 8 
Madden tried modified radical mastectomy that preserved both the 
pectoralis major and minor muscles, even though this approach prevented  
complete dissection of the apical (level III) axillary lymph nodes.7  
In the 1970s, Bernard fisher proposed that breast cancer is a systemic 
disease and along with NSABP, chemotherapy came into treatment strategy of 
breast tumour.  
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ANATOMY OF THE BREAST 
The breast or mammary gland is a Modified apocrine sweat gland 
situated in the superficial fascia of anterior chest wall. Present in both males 
and females, which is rudimentary in males. In females it starts enlarging after 
the age of puberty by the influence of hormones. 
EXTENT : 
 
1.  Vertical: 2nd to 6th ribs 
2.  Horizontal: lateral end of the sternum to mid axillary line 
3.  Base:Separated from major muscle by deep Fascia &retro mammary space 
STRUCTURE 
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1. Outer surface of the breast is convex & covered  by skin divided 
into 4 quadrants. 
 
2.  Nipple - It is a Small conical/cylindrical prominence, corresponds 
to fourth intercostal space, Surrounded by areola, thin skinned 
region lacking hair & sweat glands. 
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3. Areola- Circular dark area around the nipple contains, circular 
and radial smooth muscle fibers which Causes nipple erection. 
Montgomery’s tubercles are modified sebaceous glands 
surrounding the areola that becomes prominent during pregnancy 
and lactation. 
4. Each breast consists of ~ 20 lobes of secretory tissue  
 a.  Each lobe has one lactiferous duct 
 b.  Lobes and ducts are arranged radially 
 c.  Embedded in connective tissue &adipose tissue of 
 superficial fascia 
 d.  Lobes composed of lobules 
 e.  Lobules comprises of alveoli 
5.   Excretory (lactiferous) ducts converge toward areolaWhich 
Forms ampulla (collection sites of lactiferous sinuses),Ducts 
become contracted at base of nipple. 
6.  Secretory epithelium 
 a.  Changes with hormonal signals 
 b.  Onset of menstruation 
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 c.  Pregnancy (glands begin to enlarge at 2nd month) 
 d.  After birth, 1st secretion is colostrum (contain 
 antibodies) 
7.   “Tail of Spence” = axillary tail    
 a. Prolongation of upper, outer quadrant in the axillary 
 direction 
 b.  Passes under the axillary fascia 
 c.  May be mistaken for axillary lymph nodes. 
8.   Fatty Tissue:  surrounds surface, fills spaces between lobes that 
Determines form & size of breast. There is no fat deposit present 
under nipple & areola. Cooper’s (Suspensory) Ligaments are 
fibrous bands which is Fixed to skin & underlying fascia. 
Blood supply of the breast:  
Arterial supply: 
The arterial supply to the breast is derived from 3 main sources.  The 
predominantly from the perforating branches of the internal (thoracic) 
mammary arteries, derived from the internal thoracic artery. The breast is 
further supplied by the lateral thoracic andthoracoacromial arteries 
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(branches of the axillary artery) as well as posterior intercostal arteries 
(branches of the thoracic aorta). 
 
Venous drainage of the breast:  
Veins followarteries. Venulesform a ring around the base of the nipple 
and areola calledcirculusvenosus. Large veins pass from circulusvenosus  to 
circumference of mammary gland, then toExternal mammary vein to axillary 
vein or Internal mammary vein to subclavian vein. 
Nerve supply to the breast: 
Anterior& lateral cutaneous branches from second to sixth intercostal 
nerves.Provides sensory fibers to skin over breast & autonomic fibers to 
smooth muscles and blood vessels. 
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Lymph nodes of the breast: 
 
1.  Lateral/axillary vein group: four to six lymph nodes lying medial or 
posterior to axillary vein. 
2.  Anterior / pectoral group: four to five nodes situated along the lower 
border of pectoralis minor muscle receiving the major lymphatic 
drainage from the breast. 
3.  Posterior or subscapular group: six to seven nodes along the posterior 
border of the axilla at the lateral border of the scapula. 
4.  Central group: three to four nodes lying in the fat of the axilla posterior 
to pectoralis minor muscle, these nodes are commonly palpable in 
metastasis in breast disease. 
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5.  Apical nodes: six to twelve nodes located partly posterior and partly 
superior to pectoralis minor muscle extending to the apex of the axilla 
along the medial side of the axillary vein. These nodes receives lymph 
from all other nodes either directly or indirectly. 
6.  Rotter’s nodes: two to three nodes in-between pectoralis major and 
 minor muscle. 
 
Level I:  lymph nodes lying lateral and below to pectoralis minor 
 muscle – anterior, lateral , posterior groups. 
Level II:  behind the pectoralis minor muscle – central group. 
Level III:  above and medial to pectoralis minor muscle – apical group. 
 Other group of nodes that drain breast are:   
 Internal mammary nodes  
 Supraclavicular nodes.  
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ETIOLOGY OF BREAST CANCER 
Established risk factors 
1. Sex  
Breast cancer is about 100 times more common in females than males. 
2. Age 
Incidence of breast cancer increases with age shows rapid raise in age-
specific rates. Cancer rate continuous to rise with age,>60 years have more 
risk12 
3. Family H/o breast cancer 
Risk of cancer is greatest with first degree relatives (mother or sister) 
Some Hereditary breast cancer syndromes are: 
BRCA 1&2 genemutation-has 85 to 90% lifetime risk of developing 
breast cancer and about 40 to 65% risk for ovarian cancer 13,14  
 Li-Fraumeni syndrome 
Cowden syndrome 
Ataxia – Telangiectasia Syndrome 
Peutz – Jehar Syndrome 
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4. Fibrocystic disease with significant atypia on biopsy 
5. Previous breast cancer 
Development of a second cancer can be a manifestation of the 
multifocality of first cancer or may be an entirely new cancer. Risk appears 
about 1 percent raise per year. 
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RISK FACTORS RELATED TO REPRODUCTION 
1. Age at first pregnancy  
Women who delivers the first child at the age of >30 years has twice the 
risk of those with a first child birth before the age of 18 years 
2. Age at menarche and menopause 
Early menarche before 12 years of age, and late menopause has higher 
risk for breast cancer.15  Attaining menarche after 14 years of age have shown 
some protective  effect16 
3. Nulli-parity  
Single and nulliparous women have a relative risk of 1.4 compared to 
parous women. 
Suggested risk factors 
1. High fat diet 
Fat and cholesterol rich diet  plays a very minor role in breast cancer.17 
 
 
2. Alcohol 
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Though there is small risk of breast cancer with alcohol, now it is on a 
steady rise due to increased consumption of alcohol among women18. 
Postmenopausal women with more than one – half drink per day has 
more risk and risk steadily increases with daily alcohol consumptionrate. 
3. Oral contraceptive pills  
Risk with low oestrogen pill is small , but patients on oestrogen based 
pills shows significant risk for breast cancer 
4. Hormone replacement therapy19 
Women who used OCP for 10 or more years beginning before the age of 
35 years and before age of 18 had relative risk of about 2.2 and 3.1, 
respectively.  
Post- menopausal oestrogen replacement therapy 15 or more years is 
associated with relative risk of 1.3 for breast cancer. 
 
5. Radiation exposure 
Significant increased risk of breast cancer has been noted in survivors of 
atomic explosions .Patients receiving multiple x-rays and CT Scans are at high 
risk. There is obvious increase in risk for cancer for those women under the age 
of 35 with radiation exposure 
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6) Obesity 
There is strong relation between obesity and breast cancer, in women 
under the age of 50 there is less correlation.In the 60 to 69 age group an 
increase in weight has a 1.8 times risk for tumour. Case control studies have 
shown the traditional Japanese diet – rich in fish and vegetables and low in fat 
is protective against breast cancer. 
7) Race 
African American women and white women show increased risk for 
breast cancer relatively.12 
Protective factors for breast cancer 
1. Pregnancy before 25 years of age 
2. Adequate breast feeding 
3. Physical activity 
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PATHO-PHYSIOLOGY OF BRAEST TUMOUR 
Noninvasive Epithelial Cancers 
Lobular carcinoma in situ (LCIS)  
Ductal carcinoma in situ (DCIS) or intraductal carcinoma  
Papillary, cribriform, solid, and comedo types  
Invasive Epithelial Cancers (Percentage of Total) 
Invasive lobular carcinoma (5%-15%)  
Invasive ductal carcinoma  
Invasive ductal carcinoma, NOS (70%-80%)  
Tubular carcinoma (2%-3%)  
Mucinous or colloid carcinoma (2%-3%)  
Medullary carcinoma (5%)  
Invasive cribriform carcinoma (1%-3%)  
Invasive papillary carcinoma  
Invasive micro papillary carcinoma 
Adenoid cystic carcinoma  
Metaplastic carcinoma  
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Mixed Connective and Epithelial Tumours 
Phyllodes tumours, benign and malignant  
Carcinosarcoma 
Angiosarcoma 
NOS, not otherwise specified. 
LOBULAR CARCINOMA IN SITU (LCIS): 
o Concept of lobular carcinoma in situ was introduced by FOOTE 
AND STEWART 20 
o It’s a multicentric (more than one quadrant) tumour and occurs 
bilaterally. 
o LCIS shows proliferation of monotonous small cells in lobules, 
with bland nuclei and bubbly cytoplasm. 
o Pleomorphic LCIS is a variant with highly atypical nuclei 
o Non palpable clinically 
o LCIS is usually a incidental finding in breast biopsy 
o Calcifications are rarely associated with LCIS, so usually not 
detected in mammogram 
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o Oestrogen receptor is overexpressed in cells of LCIS whereas 
Her-2/neu is not21 
o E-cadherin is a useful marker that distinguish a lobular from 
ductal proliferation, which is usually over expressed in DCIS22 
o Invasive carcinoma occurs in 25-35% of patients with LCIS 
DUCTAL CARCINOMA IN SITU (DCIS): 
o Neoplastic growth of ductal cells in ductal system 
o Unilateral 
o Presents as a mass with or without nipple discharge 
o Mammogram shows micro calcification 
o Neoplastic cells shows varying degree of differentiation 
a) Lobular cancerization- involves lobules in DCIS 
b) Solid 
c) Papillary 
d) Micropapillary – multicentric23 
e) Cribriform 
f) Comedo – central necrosis in the ducts 
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o Low grade DCIS- ER/PR positive (91%), Her-2/neu - negative  
o High grade DCIS- ER/PR positive (57%), Her-2/neu- positive24,25 
VAN NUY’S PROGNOSTIC INDEX FOR DCIS 
SCORE 1 2 3 
Size(cm) <1.5 1.5-4 >4 
Clearance(cm) >1 1 – 0.1 <0.1 
Grade & necrosis Not high grade Not high grade High grade 
 No necrosis Necrosis + Necrosis + 
Total score is 9 
Score 3-4: conservative breast surgery 
Score 5-7: conservative surgery with radiotherapy 
Score 8-9: mastectomy  
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PAGETS DISEASE OF THE NIPPLE 
¾ Sir James Paget was the first to report eczematous changes in the 
nipple with underlying mammary carcinoma 
¾ Presents as scaling and erythema of the nipple – areola complex 
¾ Diagnosed by scrape cytology, shave or punch biopsy-shows 
carcinoma cells in the epidermis 
¾ Paget’s disease is commonly associated with underlying comedo 
type DCIS 
¾ Polyclonal CEA and CK7 are positive in Paget’s disease26,27 
INVASIVE CARCINOMA: 
Ductal (NOS type) is the most common invasive carcinoma in all breast 
cancer28-30Other types are, 
• Lobular  
• Tubular  
• Medullary 
• Mucinous  
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INVASIVE DUCTAL CARCINOMA (IDC)-NOS TYPE: 
 Presents as a palpable mass or mammographic abnormality 
 Central tumours cause tethering or inversion of nipple 
 Gross examination- hard speculated mass, gritty in nature 
 HPE – atypical cells in myriad patterns, cell nests, ducts and 
trabeculae 
 
Other types of IDC: 
1. Medullary carcinoma –  
 5% of breast cancers,common in women  with BRCA-1 
mutations 
 Young age, uncommon in elderly and males 
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 Well circumscribed carcinoma with poorly differentiated cells 
and lymphoblastic infiltrates 
 Mammogram- calcifications are seldom seen 
 Axillary metastasis are lower compared to other IDC37 
 Better prognosis 
2. Mucinous (colloid) carcinoma – 
 About 2 % incidence , elderly patients >60 years are commonly 
involved, 
 Gross examination – “pure form” is well circumscribed with 
gelatinous mass. 
 HPE – extracellular pools of mucin with few clusters of low- 
grade cells. 
 ER/PR positive, Her-2/neu – negative. 
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3. Tubular carcinoma: 
 2-4% of all breast cancer 
 Common in older post-menopausal women 
 Incidental finding in screening mammogram-speculated mass 
with or without micro-calcification 
 Typically appears as small mass less than 1 cm and scirrhous 
 HPE- more than 90% of angulated tubular structures lined by 
single layers of cells with low grade nuclei and atypia. 
 
 Overall survival is better even with lymph node metastasis38 
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4. Invasive Papillary carcinoma:39 
9 2% incidence 
9 Post- menopausal non white 
9 Well circumscribed nodular mass 
9 Papillary pattern in HPE 
5. Invasive cribriform cancer: 
 Similar to tubular carcinoma and may be found intermixed. 
 Mostly an occult mass 
 HPE – cribriform pattern and low grade cells4 
 
 Axillary metastasis  
 is lower in pure form 
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6. Basal – like carcinoma: 41 
 DNA micro array of breast carcinoma has identified this subtype 
 Her2/neu and ER negative but positive for cytokeratins and Her 
142 
 More common in BRCA1 mutation 
7. Invasive micro papillary carcinoma: 
o 51- 62 years of age  
o Size varies from 2-4cms 
o HPE- clusters of small cells in clear space 
o Only limited follow up studies are available in this. 
8. Metaplastic carcinoma: 
¾ Ductal components transformed to mesenchymal or epithelial 
elements 
¾ Most common is squamous metaplasia 
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9. Adenoid cystic carcinoma43: 
• Biologically similar to salivary glands 
• Tumour cells are small , monomorphic, cribriform or trabecular 
patterns 
INVASIVE LOBULAR CARCINOMA (ILC): 
INCIDENCE 5%- 15% of breast cancers31-33 
Presents as a palpable mass 
Also seen in mammogram 
Mass may be diffuse and not as gritty as IDC 
• Classic form: cells invade the stroma and form a single file 
pattern - ER/PR positive , Her-2/neu-negative34 
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• Pleomorphic variant: more of atypical cells and more aggressive 
than classic form35 
• Signet ring cell variant: signet ring cells in HPE , has poor 
outcome36 
Metastasis: more commonly to leptomeninges, GIT, peritoneum and 
reproductive tract than liver or lung 
 Inflammatory carcinoma: 
 Younger patients 
 Occurs when there is invasion into the dermal lymphatics 
 Breast is red, Oedematous and warm usually confused with breast 
infections 
 Punch biopsy – dermal lymphatic invasion is seen 
 Poor prognosis. 
GRAVE SIGNS of breast cancer: 
 Oedema of skin 
 Skin ulceration 
 Fixity to chest wall 
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 Axillary lymph node>2.5cm 
 Fixed axillary lymph nodes 
 
The Columbia classification based on grave signs 
Stage A: only tumour, no grave sign 
Stage B: tumour +axillary lymph nodes<2.5cm 
Stage C: tumour +any one of five grave signs 
Stage D: two or more grave signs 
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STAGING OF THE BRAEST TUMOUR  
Primary tumour (T) Definitions for classifying the primary tumour (T) 
are the same for clinical and for pathologic classification. If the measurement is 
made by physical examination, the examiner will use the major headings (T1, 
T2, or T3); if other measurements, such as mammographic or pathologic 
measurements, are used, the subsets of T1 can be used. Tumours should be 
measured to the nearest 0.1-cm increment.  
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis Carcinoma in situ 
Tis  (DCIS) Ductal carcinoma in situ 
Tis 
(LCIS) 
Lobular carcinoma in situ 
Tis 
(Paget's) 
Paget's disease of the nipple with no tumour (NOTE: Paget's 
disease associated with a tumour is classified according to the size 
of the tumour)  
T1 Tumour 2 cm in greatest dimension 
T1mic Micro invasion 0.1 cm or less in greatest dimension 
T1a Tumour >0.1 cm but not >0.5 cm in greatest dimension 
T1b Tumour >0.5 cm but not >1 cm in greatest dimension 
T1c Tumour >1 cm but not >2 cm in greatest dimension 
T2 Tumour >2 cm but not >5 cm in greatest dimension 
T3 Tumour >5 cm in greatest dimension 
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T4 Tumour of any size with direct extension to (a) chest wall or (b) 
skin, only as described below 
T4a Extension to chest wall, not including pectoralis muscle 
T4b Oedema (including peaud'orange), or ulceration of the skin of the 
breast, or satellite skin nodules confined to the same breast 
T4c Both T4a and T4b 
T4d Inflammatory carcinoma 
 
Regional lymph nodes—Clinical (N)  
NX Regional lymph nodes cannot be assessed  
N0 No regional lymph node metastasis 
N1 Metastasis to movable ipsilateral axillary lymph node(s) 
N2 Metastases in ipsilateral axillary lymph nodes fixed or matted, or 
in clinically apparent ipsilateral internal mammary nodes in the 
absence of clinically evident axillary lymph node metastasis 
N2a Metastasis in ipsilateral axillary lymph nodes fixed to one another 
(matted) or to other structures 
N3 Metastasis only in clinically apparent ipsilateral internal 
mammary nodes and in the absence of clinically evident axillary 
lymph node metastasis; metastasis in ipsilateral infraclavicular 
lymph node(s) with or without axillary lymph node involvement, 
or in clinically apparent ipsilateral internal mammary lymph 
node(s) and in the presence of clinically evident axillary lymph 
node metastasis; or metastasis in ipsilateral supraclavicular lymph 
node(s) with or without axillary or internal mammary lymph node 
involvement 
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N3a Metastasis in ipsilateralinfraclavicular lymph node(s) 
N3b Metastasis in ipsilateral internal mammary lymph nodes(s) and 
axillary lymph node(s) 
N3c Metastasis in ipsilateral supraclavicular lymph node(s) 
 
TNM Stage Groupings 
Stage 0  Tis N0 M0 
Stage I  T1   
  N0 M0  
Stage IIA  T0 N1 M0 
  T1 N1 M0 
  T2 N0 M0 
Stage IIB  T2 N1 M0 
  T3 N0 M0 
Stage IIIA  T0 N2 M0 
  T1   
  N2 M0  
  T2 N2 M0 
  T3 N1 M0 
  T3 N2 M0 
Stage IIIB  T4 N0 M0 
  T4 N1 M0 
  T4 N2 M0 
Stage IIIC  Any T N3 M0 
Stage IV  Any T Any N M1 
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CLINICAL PRESENTATION 
BREAST EXAMINATION:  
The optimal time for breast examination in the pre-menopausal women 
is 5 to 7 days after the onset of menstrual period, hormone induced breast 
changes isminimum in this period.45 
Examination should be in a systemic fashion, Breast should be 
examined with the arms raised above the head, with the arms lowered, & with 
the hands pressed against the hips. 
On inspection: 
Symmetry of the breast 
Skin over the breast 
Nipple & areola complex   
Mass if visible. 
Followed by an orderly palpation of entire breast in a radial, vertical & 
circumferential fashion, as well as in supine & erect positions  
PAIN: 
It is rare for breast cancer to present with pain46. However any women 
complaining of breast pain should be evaluated. 30-40% of pre-menopausal 
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women experience cyclical mastalgia, with exacerbation of breast pain in luteal 
phase of menstrual cycle47.Breast pain may also be due to trauma or infection 
or mimicked by costochondritis48 
PALPABLE MASS: 
 
Commonest presentation of breast cancer is painless palpable breast 
mass.With advancing age a palpable solid breast mass becomes malignant 49.In 
pre -menopausal women a palpable breast mass may be observed for 1 or 2 
menstrual cycles to see if it persists,persistent masses that occurring in post- 
menopausal women require further evaluation like mammogram, USG, FNAC 
or biopsies. 
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MALIGNANCY IN A BIOPSY OF PALPABLE MASS BASED                      
ON AGE 49 
AGE CANCER% 
20-30 2 
30-40 14 
40-50 30 
50-60 50 
60-70 73 
70-80 91 
80+ 100 
 
NIPPLE DISCHARGE: 
Nipple discharge is found in 10-15% of women with benign breast 
disease and 2.5-3% of malignancy50-51.Significant nipple discharge will usually 
be spontaneous persistent unilateral and will originate from single duct. 
Benign discharges: 
1. Galactorrhoea: Milky bilateral multi ductal discharge seen in 
pregnancy, lactation,pituitary adenoma,thyroid disease,OCP and 
drugs like phenothiazines and tricyclic anti-depressants.52 
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2.  Purulent discharge: Suggests underlying breast infection or 
abscess.This may need Incision and Drainage.50 
3. Multicoloured discharge: May range from green to grey to 
brown,usually related to fibrocystic disease and duct ectasia. 
4. Bloody nipple discharge in benign conditions is seen in 
pregnancy and post-partum. Persistent of blood stained discharge 
more than 2 months need evaluation. 
SUSPICIOUS NIPPLE DISCHARGE: 
Single duct discharges are more malignant than multi-ductdischarges53. 
Malignant discharges may be watery, serous, sero-sanguinous or bloody and 
most probably with a palpable mass. 
TYPE OF 
DISCHARGE INCIDENCE CANCER% 
Serous 41.1 6.4 
Sero-sanguinous 1.8 11.9 
Bloody 24.9 22.0 
Watery 2.2 45.4 
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SKIN CHANGES: 
 
Changes of skin of the breast include – erythema, oedema,peaud’orange 
and enlargement. Differential diagnosis includes mastitis, breast abscess, 
infected cyst ,& inflammatory breast cancer.  
Retraction,dimpling,nipple inversion may be caused by tethering of 
underlying skin or infiltration of cooper’s ligament to a underlying cancer seen 
in most advanced breast cancers. 
In late stages with lymphedema: 
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Paget’s disease of breast-dry scaly or ulcerated lesion of the nipple is 
caused by spread of an intra-ductal or infiltrating ductal carcinoma of the sub 
areolar duct to the surface of the nipple. 
Axillary lymphadenopathy: 
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Axillary lymph nodes more than 1cm is significant and needs further 
management.The incidence of breast cancer presenting as axillary 
lymphadenopathy with an occult breast primary is less than 1%. 
TUMOUR SIZE INCIDENCE OF NODAL SPREAD
<2CM 20% 
2-5CM 35% 
>5CM 50% 
 
NO OF NODES FIVE YEAR SURVIVAL RATE 
5-6 47% 
11-12 31% 
>20 8% 
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DIAGNOSIS 
DIAGNOSTIC MODALITIES 
History: 
¾ A careful history should be taken on the development and the 
characteristics of any breast abnormalities. 
¾ Side, duration, location, onset & relation to menstruation should be 
asked.  
¾ If there is a palpable mass – change in size, pain / tenderness to be 
noted.  
¾ H/o nipple discharge should be enquired – type of nipple discharge 
plays a key role in diagnosis. 
¾ Other H/o the aetiology of breast cancer like exogenous hormone 
usage, family H/o etc. 
¾ H/o previous breast biopsies or aspirations should also be taken into 
considerations especially when the reports are atypia or 
hyperplasia.44 
BREAST SELF EXAMINATION: 
 Plays a major role in detection of breast cancer in early stage 
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 Should be ideally done after menstruation, in post- menopausal age 
group, it is to be done monthly at regular intervals 
 Examine both breasts 
 In lying position with arm raised and mattress supported behind 
 Palpate using fingers over all quadrants of breast 
MAMMOGRAPHY: 
• Mammography is the best screening tool to detect breast 
abnormalities that are apparent on physical examination. 
• Mammogram is a HIGH AMPLITUDE LOW VOLTAGE X-RAY. 
Hence it should not be done if there is suspicion of pregnancy 
• Diagnostic mammogram should be taken in women older than age of 
30 in whom breast abnormality detected on examination. Nature of 
the palpable mass can be diagnosed to some extent by mammogram.  
• Negative mammogram does not rule out underlying malignancy and 
is not a reason to avoid biopsy of a palpable abnormality. 
• Mammogram can detect non-palpable breast abnormalities that help 
in detecting breast cancers in early stage. 
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VIEWS IN MAMMOGRAM: 
 STANDARD VIEW ADDITIONAL VIEW 
1.  Cranio caudal exaggerated oblique 
2.  Medio lateral slight rotational 
  Magnified 
  Tangential 
  Cleavage view 
  Axillary tail view 
  Roll view 
 
Mammographic abnormalities in carcinoma: 
1.  Clustered micro calcification. 
2.  Speculated or stellate shaped mass. 
3.  Masses with irregular margins. 
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4.  Architectural distortion. 
5.  Asymmetrical density. 
Incidence of axillary nodal involvement is about 11-13% in 
mammographically detected invasive cancers54,55 
 
Breast Imaging-Reporting and Data System: 
BIRADS 1 - Sonographically normal tissue that cause mammographic 
or clinical abnormality. 
BIRADS 2 - Benign entities (intramammary LN, ectatic duct , simple 
cyst ,definitively benign solid such as lipoma)  
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BIRADS 3 - Probably benign(<2% risk) complex cyst ,small intraductal 
papilloma ,fibroadenoma) 
BIRADS 4a - Mildly suspicious(3%-49% risk)  
BIRADS 4b - Moderately suspicious(50%-89% risk) 
BIRADS 5 - Highly suspicious( >90% risk ) 
SONOGRAM: 
It is 96-100% sensitive in detecting breast cyst56.ultrasound is less 
effective in detecting solid masses. If it is an unclear mass cystic or solid 
FNAC can be used to determine the nature of the mass. 
A cancer presenting only on USG which was negative on clinical 
examination and mammogram is 1.8% 57 
FNAC: 
Fine needle aspiration cytology.it is done using 20-22 gauge needle 
attached to 10 or 20ml syringe by maintaining negative pressure on the syringe. 
Uses of FNAC: 
1. To determine whether a mass is cystic or solid. 
2. To obtain cytologic sample of a breast abnormality. 
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Unlike ultrasound FNAC is invasive minimally painful procedure. 
COMPLICATIONS of FNAC: 
1. Ecchymosis 
2. Haematoma 
3. Infection 
FNAC scoring: 
Co – no epithelial cells  
C1 – scanty epithelial cells 
C2 – benign cells 
C3 - atypical cells 
C4 – suspicious cells 
C5 – malignant cells 
MRI : 
MAGNETIC RESONANCE IMAGING. Screening breast MRI has a 
role in women who are at high risk of developing breast cancer,particularly if 
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they have dense breast on mammogram. Due to its low specificity and high 
cost it’s not use in regular screening 58 
MRI is complementary not an alternate to mammogram59. It can be 
helpful in evaluating the breasts for an occult primary tumour in patients who 
present with an adenocarcinoma metastatic to axillary lymph nodes or distant 
sites when there are no breast abnormalities on physical examination or 
mammography. 
MRI helps in differentiating scar and recurrence. 
CORE BIOPSY: 
Less invasive biopsy techniques have been developed to perform open 
biopsies for benign disease 60. 
Core biopsy provides an expedient, less invasive, less expensive means 
of obtaining a histologic diagnosis of mammographic or palpable breast 
abnormalities. 
An open biopsy provides more information that to help in local 
treatment decisions, such as tumour size, histologic type, presence of an 
extensive intra-ductal component, and margin status. 
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A core biopsy can be used to evaluate palpable masses. One advantage 
of the core biopsy is that a skilled cytopathologist is not needed for 
interpretation of the slides, as is the case for FNA cytology. 
IMAGE GUIDED BIOPSIES: 
Nonpalpable lesions can be examined via core biopsy with stereotactic, 
sonographic, or MRI guidance, depending on in which study the lesion is best 
seen. 
SURGICAL BIOPSY: 
There two types of open or surgical breast biopsies.    
1. Incisional biopsy – Removes only a portion of the lesion. TRU –
CUT & Core needle are variants of incisional biopsy. 
2. Excisional biopsy – It completely removes the biopsy ,Local 
anaesthesia or iv sedation can be used for the procedure. 
Curvilinear incision parallel to langhers line is used; this incision 
might be incorporated into a mastectomy incision later. Frozen 
section histology to be done in suspicious cases that helps in 
completing definitive surgery in single sitting. 
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INVESTIGATIONS FOR METASTATIC WORK UP: 
1. BLOOD INVESTIGATIONS: 
Routine blood investigations and liver function tests. Alkaline 
phosphatase level is elevated in bone and liver metastasis. 
2. CHEST X-RAY: 
Chest wall is the first site of recurrence in 5-30% of breast carcinoma 
patients. Most of the patients will be symptomatic with chest metastasis. It 
affects 
• Pleura 
• Parenchyma 
• Ribs 
• Mediastinum 
• Pericardium 
3. ULTRASOUND: 
¾ Liver secondaries 
¾ Ascites  
¾ Krukenburg tumour 
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¾ Pleural effusion. 
4. SKELETAL SURVEY: 
 X RAY skull anteroposterior/lateral. 
 X RAY spine- cervical, dorsal ,lumbar 
 X RAY long bones-femur, humerus. 
5. CT SCAN: 
• Doubtful lesions of metastasis on X-RAY and USG can be detected 
appropriately. 
• Can pick up internal mammary nodes 
• Small lung and liver secondaries. 
6. HORMONE RECEPTOR STATUS 
 ESTROGEN RECEPTOR (ER) 
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 PROGESTERONE RECEPTOR(PR):  
 
 These are expressed in tumour cells of breast carcinoma.  
 Helps in determining the type of chemotherapy and hormonal 
therapy. 
 Receptor positive patients show comparative survival advantage over 
receptor negative patients. 
7. HER-2/neu STATUS: 
o It is a member of epidermal growth receptor family.it is over 
expressed in 20-30% of invasive breast cancers61. 
o Her 2 status is measured by immunohistochemistry and fluorescence 
in situ hybridisation. 
o Her 2 positive patients has worst prognosis. 
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8. BONE SCAN: 
Bone is the most common site for systemic metastasis. Early pick up 
rate 10-15% in asymptomatic patients83.High sensitivity. Axial skeleton is 
more involved than ribs, long bones, skull. 
 
9. PET SCAN: 
F-18 FDG:Was introduced in 1989.It uses a specially modified gamma 
camera helps in visualising metastatic tumours and lymph nodes.It is 
adominant modality for advanced breast disease. 
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PET scan is used for staging of distant metastasis and re staging for loco 
regional recurrence and monitoring response to therapy. 
 
Sentinel Lymph Node Biopsy in Breast Cancer: 
Axillary lymph nodes are the most reliable clinical predictors of 
outcome in breast cancer and the survival of the patient. In order to optimally 
plan for the management of breast cancer 
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The gold standard method of assessing axilla is histo-pathological 
examination and all other methods need to be compared against this for 
accuracy and utility. This has made axillary dissections almost a mandatory 
part of management of breast cancer. 
However with the advent of SLNB, it has been made possible to assess 
axilla without performing morbid axillary dissections in node negative patients. 
First axillary node draining the breast is called sentinel node, incidence 
of other nodes without SLN is < 3% 
Done in cases of early breast cancer- T1 and T2 without clinically 
palpable nodes 
It is not done in clinically palpable nodes and in multifocal multicentric 
tumours due to distortion of lymphatic flow 
Technique: 
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Preoperative (within 12 hours) or per-operative injection of isosulfan 
blue dye 2.5-7.5 ml or TC 99 labelled albumin near the tumour or into sub 
dermalplexus around the nipple (peritumour injection is relatively better) 
Marker to the sentinel node is visualised either by blue staining or hand 
held gamma camera respectively, detection rate for blue dye and radioisotope 
90% and 98% respectively 
 
Frozen section biopsy or touch imprint is done,if there is no involvement 
of SLN further axillary dissection is not required 
Positive SLNB is classified as macro metastasis(> 2 mm) 
Micro metastasis (< 2 mm) 
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Contraindications: 
• Allergic to dye or radio colloids 
• Pregnancy 
• Inflammatory carcinoma of breast 
Complications: 
¾ Allergic reactions 
¾ Blue coloured urine and stool  
¾ Seroma 
Skip lesions in 3% of cases SLN may be skipped 
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TREATMENT 
VARIOUS MODES OF TREATMENT FOR BREAST CARCINOMA 
 Surgery 
 Radiotherapy 
 Chemotherapy 
 Hormone therapy 
SURGERIES FOR BREAST CANCERS: 
1. Conservative breast surgery: complete surgical excision with good 
Cosmetics 
Indication: 
 Single primary tumour <4cms  
 Clinically negative nodes 
 Mammographically detected lesion  
 Able to excise completely with negative margin  
 Decreased tumour to breast ratio 
 Patients who can come for proper follow up 
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It may even be suitable for women with large breasts in whom the 
tumour is up to 5 cm or even multifocal tumours confined to the same quadrant 
and when large operable tumours have been down-staged by neo-adjuvant 
chemotherapy62 
¾ Wide local excision(lumpectomy) : Removal of unicentric tumour 
with 1 cm clearance, axillary dissection with separate incision can be 
done. Post op RT to breast and axilla can also be given after wide 
local excision 
¾ Quadrantectomy : Removal of entire segment or quadrant with 
ductal system- 2-3 cm clearance 
¾ QUART therapy:Quadrantectomy + axillary dissection (level I & II 
clearance) + radiotherapy 
¾  Skin sparing mastectomy-presently gaining much interest and 
practiced by many surgeons.  
Local recurrence rates after breast conservation surgery are kept at about 
1 % per annum 63 
Contraindications: 
• Large tumours > 4 cms 
• Multicentric tumours 
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• Tumour beneath nipple 
• Pregnancy /connective tissue disorders 
• Inability to achieve negative margin after surgery 
• Previous radiotherapy to breast region 
1. Simple mastectomy: 
• Entire breast, skin, nipple areolar complex, axillary tail along with 
the breast   mass 
• Pectoral fascia is also removed 
• External beam radiotherapy to the axilla can be given 
postoperatively. 
2. Total mastectomy with axillary clearance: 
Total mastectomy with level I &II axillary nodes are removed 
3. Radical mastectomy: 
Halsted’s radical mastectomy- 
Structures removed are :- 
o Entire breast, skin, nipple areolar complex, axillary tail along with 
the breast mass 
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o Pectoralis major and minor muscle 
o Fat, fascia and lymph nodes 
o Few digitations of serratus anterior muscle 
Structures preserved are: - 
Axillary vein, bells nerve, cephalic vein 
This procedure is not done commonly nowadays, complications are- 
lymphedema, lymphangiosarcoma 
4. Modified radical mastectomy: 
o Patey’s mastectomy: 
 Total mastectomy + level I ,II,III axillary nodes + pectoralis minor 
muscle 
 Pectoralis major muscle is also preserved 
o Scanlon’s mastectomy :  
 It is a modified patey’s procedure in which pectoralis minor muscle 
is incised  
o Auchincloss mastectomy:  
 Pectoralis minor muscle is left intact, level III nodes are not 
removed.  
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 It is commonly done nowadays 
6. Extended radical mastectomy: 
Radical mastectomy with internal mammary nodes are removed 
7. Super extended radical mastectomy: 
Supraclavicular nodes are also removed + Extended radical mastectomy 
8. Toilet mastectomy: 
In advanced breast tumours, this procedure is done as a palliative 
treatment 
9. Breast reconstruction: 
• Oncoplastic techniques 
• Breast implants or expanders. 
• Flap with implants or expanders. 
• Flap reconstruction-  
• LD flap- based on sub-capsular artery. 
• TRAM flap- superior epigastric artery. 
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TYPES OF SKIN INCISION: 
 Stewart  
 Kocher’s 
 Orr  
 Rodman 
 Greenough 
 Gray – it extends to the opposite breast 
COMPLICATIONS OF MASTECTOMY: 
• Injury /thrombosis of axillary vein  
• Seroma 
• Pain and numbness 
• Flap necrosis/infection 
• Lymphedema 
RADIOTHERAPY: 
Dosage:5000 cGY units  
200 cGY daily 5 days a week for 5 weeks 
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Indications:- 
After Conservative breast surgery- to the breast 
After total mastectomy- to the axilla 
Patients in high risk category: after surgery 
• Extensive in situ carcinoma 
• Invasive carcinoma 
• Patients < 35 years 
• In Her2/neu positive patients 
• Patients with multi focal disease 
In case of bone secondaries, to palliate pain and swelling. 
Inflammatory carcinoma of breast. 
Preoperative RT to down stage the tumor to make it operative. 
RADIOTHERAPY 
To chest wall To Axilla 
T3 tumor > 5 cm More than 4 positive lymph nodes 
Residual disease – LABC extra nodal spread. 
+ve surgical margins Unknown nodal status 
After conservative surgery  
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 Tangential fields 50GY/25 fractions 5 weeks 
 Other 10 GY to tumor bed 
 Internal mammary and supra clavicular nodal area may be included. 
CHEMOTHERAPY: 
1. First line drugs:Anthracyclines:CMF,CAF 
2. Second line drugs:Taxanes-paclitaxel, docetaxel. 
3. Third line drugs: Gemcitabine. 
Chemotherapy drugs are given as one day dose of the regimen at 3 
weekly cycles for 6 cycles for LABC.3 cycles pre operatively and 3 cycles after 
mastectomy is currently followed. 
Neo adjuvant chemotherapy: It reduces the loco regional tumour burden, 
three cycles every 21 days it down stages the disease.it makes inoperable 
tumour to operable one. May achieve early systemic control.Can be used in 
selected cases for breast conservation. 
Adjuvant chemotherapy: Administered after surgery for breast cancer 
patients. Reduces recurrence and prevents undetectable distant spread. Overall 
improves the survival rate. 
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Palliative chemotherapy:Used in advanced and metastatic breast 
cancers. 
TYPES OF CHEMOTHERAPEUTIC DRUGS AND ITS 
COMBINATIONS: 
DRUG 
COMBINATION 
DRUG NAMES 
CMF CYCLOPHOSPHAMIDE , METHOTREXATE , 
5-FLUOROURACIL 
FAC(CAF) CYCLOPHOSPHAMIDE , 
ADRIAMYCIN(doxorubicin),  
5-FLUOROURACIL 
AC CYCLOPHOSPHAMIDE , 
ADRIAMYCIN(doxorubicin), 
TAC DOCETAXEL(TAXOTERE), 
CYCLOPHOSPHAMIDE, 
ADRIAMYCIN(doxorubicin) 
AC  -    T CYCLOPHOSPHAMIDE , 
ADRIAMYCIN(doxorubicin) FOLLOWED 
BY)PACLITAXEL(TAXOL)/ 
DOCETAXEL(TAXOTERE 
CT CYCLOPHOSPHAMIDE , 
DOCETAXEL(TAXOTERE), 
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DOSAGES OF CHEMOTHERAPEUTIC DRUGS: 
1. Cyclophospamide 400-600mg/m2 
2. Methotrexate 40-60mg/m2
3. 5 Fluorouracil 500mg/m2
4. Doxorubicin 50-60mg/m2
5. Docetaxel 80-100mg/m2 
6. Paclitaxel 175mg/m2
7. Gemcitabine 800-1250mg/m2 
 
Indications for chemotherapy: 
1.All node positive patients 
2.Tumour size >1cm. 
3. Inflammatory carcinoma. 
4. Her -2/neu positive hormone receptor negative status. 
5. Stage 4 cancer with distant metastasis. 
6. Post-operative period after mastectomy in stage 3 cancer. 
Chemotherapy and radiotherapy can be given concurrently or as a 
sandwich therapy. 
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Hormone therapy: 
o Helpful in ER/PR positive patients in all age group. 
o Safe and easy to use. 
o Useful in metastatic breast cancers. 
o Protects cancer metastasis/primary tumour in opposite breast. 
o Reduces recurrence rate and improves quality of life. 
Types of hormone therapy: 
• Oestrogen receptor antagonist:Tamoxifen. 
• LHRH agonists-goserelin 
• Aromatase inhibitors: letrozole, anastrozole, exemestane. 
• Progesterones:Medroxy progesterone  
• Androgens: Injection testosterone propionate. 
TAMOXIFEN 
It acts against cytosolic oestrogen receptors. 
Dosage: 10mg bid or 20mg OD for 5 years. 
Half- life:- 7 days. 
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Advantages: 
 Reduce recurrence rate 25% 
 Helps in better prognosis. 
 Used in all age groups  with ER positive status 
 Cheap, less toxic, very effective. 
Side effects: 
• Tamoxifen flare 
• Bone pain 
• Increased chance of endometrial cancer. 
• DVT/CVA/TIA/Pulmonary embolism. 
 RALOXIFENE 
 Selective oestrogen receptor antagonist which has less side effects and 
less incidence of endometrial cancer compared to Tamoxifen. 
LETROZOLE 
Prevents the Conversion of adrenal androgens to estrogen. 
Costly,but effective in Oestrogen sensitive breast tumours. 
Half -life:45hrs. 
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Dosage: 2.5mg od given for five years or 2 years followed by 3 years of 
tamoxifen. 
Side effects:Vaginal dryness,Hot flushes,Osteoporosis,Night sweats. 
Tamoxifenmonotherapy&letrozolemonotherapy  for 5 yrs shows better 
results compared to switch protocol with 2yrs of treatment with one agent and 
next 3 yrs with other 
TRANSTUZUMAB(HERCEPTIN) 
It is a monoclonal antibody acts against HER2 neu receptors. 
Less effective in HER2-neu negative patients. 
Dosage:4mg/kg loading,2mg/kg as maintenance for 1 year. 
Cardio toxic 
Improves disease free and overall survival rate. 
DRUG OF CHOICE: 
Pre-menopausal Post-menopausal 
Tamoxifen Tamoxifen 
Progesterone Progesterone 
Androgen Androgen 
Ovarian ablation Letrozole 
 Medical adrenalectomy-using amino glutethimide 
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OVARIAN ABLATION AND OVARIAN FUNCTIONAL 
SUPPRESSION: 
1. Ovarian ablation: Oophorectomy or radiation. 
2. Functional suppression:LHRH Hormone agonist 
It has therapeutic benefit in pre- menopausal women in early breast 
cancer.64 
Hormone receptor patients and invasive cancer patients are benefitted by 
ovarian ablation procedure. 
LOCALLY ADVANCED BRAEST CARCINOMA{LABC} 
 Breast tumour of more than 5cms of size 
 Skin involvement with muscle or chest wall involvement 
 Mobile to fixed axillary lymphnodes 
 Stage IIB, III A & Stage III B. 
 T3, T4a, T4b, T4c, T4d, and N1 to N3. 
After completely evaluating the patient with FNAC, core needle biopsy, 
mammogram of opposite breast, chest X-ray, USG, CT chest and abdomen, 
bone scan if possible. 
Size of the tumour, axillary status & staging of the tumour to be done. 
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Present treatment strategy for LABC: 
1. Neo adjuvant chemotherapy(3 cycles) to down stage and achieve 
cyto-reduction,reduce the micro metastasis. 
2. Response to chemotherapy is assessed: 
Complete responders- without palpable mass, partial responders- more 
than 50% reduction in tumour size,non-responders-less than 50% reduction in 
tumour size. 
3.Responders are treated by MRM, post operatively remaining 3 cycles 
of chemotherapy are completed, followed by hormone therapy(tamoxifen -5 
years) for hormone receptor positive cases. 
4. Non responders are treated by 2nd line of chemotherapy (taxanes), RT 
to breast, chest wall and axilla.Hormone therapy and surgery if possible. 
Metastatic breast cancers:STAGE 4: 
• Bone is the most common site of metastasis, followed by lung, liver, 
pleura, and brain. 
• Median survival of the patient is 24months. 
• Treatment strategy 
• To improve quality of life 
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• To relieve pain due to secondaries in bone and lung. 
• Palliative surgeries 
• Symptomatic relief 
Cause of death in breast carcinoma: 
Lung secondaries- respiratory failure, haemoptysis. 
Spine secondaries-quadriplegia 
Secondaries in brain 
Cancer cachexia 
Prognostic factors in breast cancer: 
Good prognosis Worst prognosis 
Stage 1 and 2 Stage 3 and 4 
Female Male 
 Younger age 
Medullary carcinoma Inflammatory carcinoma 
ER positive Her 2 neu positive,353,aneuploidy 
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FOLLOW UP  
Loco regional recurrence- 
 Patients are observed at 6 months interval clinically and one year 
with mammography of opposite breast. 
 Single or multiple subcutaneous or intra cutaneous nodules on chest 
wall near mastectomy scar.65-69 
 Pectoralis major is rarely involved70 
 Carcinoma en cuirasse-diffuse infiltration of tumour in skin and 
subcutaneous tissue of the chest wall. 
 Regional nodal recurrence can occur to residual nodes, 
supraclavicular or cervical node. 
 Investigations done with FNA or punch biopsy or incisional biopsy. 
 Surgical resection alone of an apparently isolated local recurrence is 
followed by further local failure in 60-75% of patients71-74 
 Management: Surgical resection of skin, subcutaneous tissue of full 
thickness upto chest wall can give 75% of disease control. 
 Patients who have not received previous chest wall irradiation can be 
treated with local excision with radiation. 
 Systemic therapy with tamoxifen improves the outcome to one 
extent.75,76 
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Surveillance of distant metastasis: 
 Examination at 3-6 months interval for first 5 years with blood count 
and LFT in every visit  
 Annual chest x ray 
 Bone scan 
 Recurrences are more common in bone,lungs,liver.77,78 
 Most recurrences are detected within 7-8 years. 
 Stage of Primary tumour + axillary nodal status plays an important 
role in recurrence.79,80 
 Surveillance for second primary breast cancer in contralateral breast 
 0.4-0.7% per year in second primary breast cancer.81,82 
 Self-Breast examination,clinical breast examination and annual 
mammogram are used for screening. 
 CEA or CA 15-3 ,mammary cancer antigen ,mammary serum 
antigen84-89 
 Alkaline phosphatase enzymes are elevated in 30-50% of patients 
with bone metastasis90-91 
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PATIENTS, MATERIALS AND METHODS 
Among the patients who have attended the surgical outpatient 
department in our hospital (GMKMCH). 
In total of 105 female breast cancer patients admitted in our surgical 
wards, 70(66%) patients were in locally advanced stage.Those 70 patients were 
taken up for our study. 
EXCLUSION CRITERIA –  1. Benign Breast conditions 
                                                2. Early breast cancers 
                                                 3. Metastatic breast cancers   
                             4. Male breast cancer     
Complete history, physical examination, lab investigations, imaging 
studies, ECG, ECHO,FNAC where done to confirm the diagnosis and 
treatment was planned accordingly. 
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Neo-adjuvant chemotherapy was given for all the patients,FAC regimen 
3 cycles preoperatively,each cycle in about 21days interval. Clinical response 
for chemotherapy is studied after every cycle. 
Patient with good clinical response were planned for surgery. All 
patients underwent Modified radical mastectomy with axillary clearance, after 
completing neo-adjuvant chemotherapy with in a period of 3 weeks.  
ER/PR, HER2-neu was done in mastectomy specimen for other patients 
to know the receptor status and further management. 
HER2-neu positive patients were referred to higher centre for next line 
chemotherapy due to its non-availability in our Hospital 
Post operatively patients received 3 more cycles of adjuvant 
chemotherapy. Patient’s history,clinical examination, blood investigations were 
done during each visit. 
Patients with poor response to neo-adjuvantchemotherapy were given 
the full course of 6 cycles of chemotherapy then followed by surgery. 
Postop Radiation therapy was given for all the patients to the tumour 
bed & axilla to prevent further progress of the tumour if any. 
Tab.Tamoxifen 10mg BD was given for all patients and advised to 
continue for 5 years 
Patients were followed up for recurrence and metastasis. MRI scan, PET 
scan & BONE scan was done for symptomatic cases 
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OBSERVATION AND DISCUSSION 
1. Age at presentation: 
In our study group patients age ranges from 27 - 75 years and the 
maximum number of patients were in range of 40-49 years. 
TABLE: 1 
           Study group Number of patients                Percentage 
<39 11 16% 
40-49 26 37% 
50-59 16 23% 
>60 17 24% 
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Chart 1.  Age at presentation 
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2. PARITY & MENSTRUAL STATUS 
4 patients of 70 were nulliparous (5.7%) 
Other patients had children and breast feeding done adequately 
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Table 2. Menopausal status 
Study group 
post-menopausal 
pre-menopausal 
Number of patients Per
45 
25 
centage 
64% 
36% 
 
In our study group most of the patients were in post-menopausal state 
 
 
Chart 2. menopausal status 
pre-menopausal
post-menopausal
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3. PRESENTING SYMPTOMS OF THE PATIENTS 
Symptom no. of patients Percentage 
Breast mass 70 100% 
pain 43 61% 
Nipple discharge 12 17% 
ulcer 18 26% 
 
Presenting complaints of all the patients were breast mass  
Around 61 % came with complaints of pain over the swelling, 17% with 
nipple discharge & 26 % with skin infiltration and ulcer. 
Though every patient has mass in the breast, the symptoms which 
brought them to the hospital were pain and ulcer over the breast.   
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4. SIDE & QUADRANT OF BREAST LESION: 
Table 3. 
SIDE & QUADRANT    NUMBER OF PATIENTS 
RUO 25 
RUI 3 
RLI 2 
RC 9 
LUO 15 
LUI 8 
LLI 1 
LC 7 
 
Most of the patients presented with right upper and outer quadrant lesion 
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CHART 3. Side & quadrant of breast lesion 
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5. STAGE OF THE TUMOUR: 
TNM staging of breast tumour on clinical and radiological evaluation 
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Table. 4  
Stage of tumour Number of patients 
T2N1M0 2 
T3N1M0 32 
T3N2MO 2 
T4aN1M0 1 
T4bN1M0 21 
T4cN2M0 1 
T4bN2M0 8 
T4bN3M0 3 
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CHART 4. STAGE OF THE TUMOUR 
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6. Response to neo-adjuvant chemotherapy: 
CAF Regimen is given for all patients after complete investigation and 
cardiac evaluation 
CYCLOPHOSPHAMIDE – 400- 600 mg/m2 
ADRIAMYCIN(doxorubicin)- 50-60mg/m2 
 5-FLUOROURACIL – 500 mg/m2 
This regimen is given in one day as IV infusion in a good patent vein 
consecutively, 
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Each cycle has an interval of  21 days,all routine investigations were 
repeated before each cycle. 
Out of 70 patients of LABC  
1.   49 patients were given 3 cycles of  neo-adjuvant chemotherapy 
(CAF regimen) following which surgery was done 
2.  12 patients were given 2 cycles of  neo-adjuvant chemotherapy 
(CAF regimen) following which surgery was done 
3.  2 patients were operated without neo-adjuvant chemotherapy 
 
  
86 
 
TABLE 5. Neo-adjuvant chemotherapy 
Type of re
 
CAF
gimen No. cycles of neo-
adjuvant chemo 
N
 
3 
2 
0 
6 
o. of patients 
49 
12 
2 
4 
 
CHART 5 . Neo-adjuvant chemotherapy 
0
5
10
15
20
25
30
35
40
45
50
3 2 0 6
 
 
 
87 
 
Most of the patients in the study responded well to CAF regimen of 
Chemotherapy 
>40 – 50 % tumour size reduction were noted in 64 patients(2 patients – 
no chemotherapy) 
4 patients who responded <25% to 3 cycles of chemotherapy were given 
3 more cycles of CAF regimen and taken up for surgery 
7. ER / PR / HER2 neu STATUS: 
Hormone receptors were done only for 13 cases. Among those patients  
HORMONE STATUS Out of 13 patients 
ER+/PR-/ HER2neu - 2 
ER+/PR+/ HER2neu - 2 
ER-/PR+/ HER2neu+ 1 
ER-/PR -/ HER2neu + 2 
ER-/PR -/ HER2neu - 6 
 
88 
 
0
1
2
3
4
5
6
ER+/P
HER2n
Hormone rece
more or less similar t
3 HER2 neu p
chemotherapy since 
8. SURGERY - MA
70 cases und
axillary clearance .pr
was needed for one p
MRM: An ell
3rd intercostal spac
laterally into the axi
ptor positive patients and negative patien
o chemotherapy 
ositive cases were referred to higher cent
only CAF regimen is available in our hosp
STECTOMY [MRM]: 
erwent modified radical mastectomy wi
imary closure was possible for 69 cases a
atient 
iptical incision is made from medial aspe
e enclosing the nipple, areola and tu
lla along the anterior axillary fold, uppe
R-/ 
eu -
ER+/PR+/ 
HER2neu -
ER-
/PR+/ 
HER2neu+
ER-
/PR -/ 
HER2neu 
+
ER-
/PR -/ 
HER2neu -
Out of 13 patients
 
ts responded 
re for next line of 
ital. 
th level I and II 
nd reconstruction 
ct of the 2nd and 
mour extending 
r and lower skin 
89 
 
flaps are raised. Breast along with tumour is raised from the medial aspect of 
the pectoralis major muscle. Mastectomy completed. 
 
 
(a) Lateral border- Anterior margin of the latissimusdorsi muscle  
(b) Medial border - Midline of the sternum  
(c) Superior border -The subclavius muscle 
(d) Inferior border - The caudal extension of the breast, which is 3 to 4 
cm inferior to the inframammary fold 
AXILLARY DISSECTION: After completing mastectomy, dissection 
reaches to the axillary region, level I & II axillary nodes are cleared till axillary 
vein is reached 
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AXILLARY VEIN 
MRM with FLAP reconstruction: 
One patient - who was a partial responder to neo-adjuvant chemotherapy 
{CAF regimen} for whom all 6 c y completed and taken 
Intra op & post -operative was uneventful except 2 patients developed 
wound
ycles of chemotherap
up for surgery.  
Since complete skin cover could not be achieved MRM along with LD 
flap was done. 
 gapping 
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Specimen: resected breast tissue with axillary nodes. 
 
Specimen sent for histo-pathological examination 
All the histo-pathological reports were reported as Invasive Ductal cell 
Carcinoma – NOS type, except one which was found to be mucinous type. 
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IDCC 
9. POST OPERATIVE -ADJUVANTCHEMOTHERAPY: 
Patients, who were given 2 or 3 cycles of chemotherapy preoperatively, 
completed rest of chemotherapy at 21 days interval after surgery. At every 
visit, routine blood investigations along with LFT, ECG, ECHO, X -ray were 
done routinely. In selected patients MRI spine and CT chest were also done.  
10. RADIOTHERAPY: 
After completing adjuvant chemotherapy, patients were subjected to 
external beam radiotherapy in radiotherapy department in GMKMCH. 
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CHEST WALL – 50GY -200cGY – 25 fractions- Tangential Followed 
by scar boost -10 GY – 200cGY – 5 fractions (With electrons) 
Drainage – Supraclavicular / Axilla 50G – 250cG -20 fractions 
Followed by P/A boost to reach 50 G to axilla 
BONE METS  30G – 300cG – 10 fractions 
Margins involved RT first 
11. HORMONE THERAPY: 
Tamoxifen 20mg per day is prescribed for all patients except, confirmed 
receptor negative cases  
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12. FOLLOW – UP: 
Patients were asked to come for follow-up every 3 to 6 months for 2 
years. 
Patients with symptoms were evaluated by routine blood investigations, 
x-ray, USG, FNAC, MRI, Respectively. 
7 patients didn’t come for follow-up after surgery, and 4 more lost 
follow-up after completion of Adjuvant chemotherapy.   
LYMPHEDEMA: 
 
 3 patients presented with lymphedema in upper limb of the operated 
site within 3 months of surgery. 
 They were treated conservatively with limb elevation, 
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 Elasto-crepe bandage anti-inflammatory agents. 
 Breast cancer patients with upper limb lymphedema who follow a 
program of slow progressive weight lifting have a decreased 
incidence of exacerbations of lymphedema ,  reduced symptoms and 
increased strength 
RECURRENCE &METASTASIS : 
In the remaining 56 cases in my study out of which 3 cases had local 
recurrence,4 vertebral metastasis, 1 liver metastasis & 1 brain metastasis 
Local recurrence: 
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Vertebral metastasis: 
 
RECURRENCE + 
METASTASIS 
NO. OF PATIENTS 
OUT OF 56 
PERCENTAGE 
LOCAL RECURRENCE 3 5.3% 
VERTEBRAL METS 4 7.1% 
LIVER METS 1 1.8% 
BRAIN METS 1 1.8% 
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Recurrences were noted with in about 4-12 months of adjuvant 
chemotherapy/ radiotherapy. 
Liver metastasis was the early to present in about 4 months – with 
jaundice 
Brain metastasis patient presented in end-stage 5 month after completion 
of RT – patient was unconscious with minimal response to painful stimuli 
Patients withVertebral metastasis was treated by radiotherapy - 30G – 
300cG – 10 fractions 
Local recurrence patients were further evaluated with FNAC, CT &MRI 
.wide local excision was done for 3patients and advised chemotherapy, but 
only one patient turned up for chemotherapy. 
SURVIVAL RATE: 
5 patients died within the time period of the study – those include  
• 1-Liver metastasis 
• 1-Brain metastasis 
• 2-Vertebral metastasis 
• 1-other cause 
• 2 year survival rate was around 89 % in this study. 
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CONCLUSION 
 In the overall patients of breast cancer admitted in surgical ward, 66% 
were found to be in LABC stage that is in stage IIa, IIIa, IIIb of TNM 
classification. 
 The highest age incidence of locally advanced breast carcinoma in my 
study population ranges from 40-49 years of age. 
 5.7% in the study group were nulliparous, No other Established risk 
factors for development of breast cancer were present in these patients. 
LABC is predominantly in post-menopausal age group. 
 Though every patient of LABC had complaints of lump in the breast, the  
symptoms which brought them to the hospital is not the lump in 
majority of cases. Most patients came to OPD for pain over the lump, 
skin ulcer or nipple discharge. Thus awareness towards breast cancer 
should be improved to pick up cancer in early stage .knowledge of self-
breast examination to the population will achieve this target 
significantly. 
 The site of occurrence of LABC on the right side in the upper outer 
quadrant of the breast. 
 TNM Stage III B is the common stage of LABC in this group of people. 
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 Most of the patients responded very well to Neo-adjuvant chemotherapy 
inspite of hormone receptor status. No major side effects was there to 
chemotherapeutic drugs except for alopecia in most and nausea and 
vomiting for few, And there was a significant reduction in tumour size 
thus providing good surgical clearance and reducing systemic spread of 
the tumour. 
 MRM is the surgery of choice which gives both local and axillary 
clearance. 
 Neo-adjuvant chemotherapy, MRM followed by adjuvant chemotherapy 
and radiotherapy helps in reducing local recurrence to about 5% and 
systemic metastases of about 7%. 
 Overall 2 year survival rate in the study group was about 89%. 
 In nut shell prognosis and survival rate in breast cancer can be improved 
by awareness on health education, self-breast examination and screening 
mammogram will help in picking up breast cancers in early stage. In 
case of locally advanced breast cancer proper clinical and radiological 
evaluation followed by neo-adjuvant chemotherapy that helps in 
reducing systemic micro-metastasis. Mastectomy with good axillary 
clearance and adjuvant therapy there by improves the overall survival 
rate in LABC patients.  
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ANNEXURES 
1. PROFORMA 
LOCALLY ADVANCED BREAST CARCINOMA 
NAME:                                    AGE:          SEX:        IP.no: 
 
OCCUPATION: 
SOCIOECONOMIC STATUS: 
 
CLINICAL HISTORY 
1.  PRESENTING C/O: 
1.  SWELLING- 
2.  PAIN- 
3.  NIPPLE DISCHARGE- 
4.  NIPPLE RETRACTION 
5.  LOSS OF APPETITE & WEIGHT- 
 
ii 
 
6.  SYMPTOMS SUGGESTIVE OF METASTASIS: 
  i) BACK ACHE 
  ii) CHEST SYMPTOMS 
  iii) JAUNDICE 
        iv) HEAD ACHE & CONVULSIONS 
  v) OPPOSITE BREAST 
7. OTHER SYMPTOMS 
  FEVER 
  MALAISE 
2.  PAST HISTORY: 
       H/O  -  HT/DM/TB/BA/HEART DISEASE- 
  H/O  -  SIMILAR SWELLING IN THE BREAST- 
  H/O  -  PREVIOUS SURGERIES-  
3.  FAMILY H/O: 
4. DRUG H/O:   
  H/O - OCP INTAKE / HRT 
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  H/O-  RADIATION EXPOSURE 
5.  MENSTRUAL H/O: 
  AGE AT MENARCHE 
  MONTHLY MENSTRUAL CYCLES 
  AGE AT MENOPAUSE 
6. MARITAL H/O: 
  AGE AT MARRIAGE 
7. OBSTETRIC H/O: 
  PARITY 
  NUMBER OF CHILDRENS 
  AGE OF PATIENT AT LAST CHILD BIRTH 
  DURATION OF BREAST FEEDING 
8. PERSONAL H/O: 
  H/O SMOKING & ALCOHOL 
  DIET H/O 
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EXAMINATION 
GENERAL EXAMINATION: 
 
 
 
LOCAL EXAMINATION 
BREAST:   SIDE: 
                  QUADRANT: 
                  TUMOR SIZE: 
                  CONSISTENCY: 
                  SKIN/CHEST INVOLVEMENT: 
   MOBILITY: 
   NIPPLE  & AREOLA: 
   ULCER/ SCAR/ SINUS: 
   NODAL STATUS: 
   OPPOSITE BREAST AND AXILLA: 
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OTHER SYSTEMS EXAMINATION 
 ABDOMEN 
 CVS 
 RS 
 CNS 
 SPINE AND CRANIUM 
INVESTIGATIONS 
1. BLOOD PARAMETERS 
2. MAMMOGRAM 
3. FNAC 
4. X-RAY CHEST,SKULL,LONG BONES 
5. USG ABDOMEN & PELVIS 
6. ECG 
7. ER , PR  / HER2-nu  
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STAGING 
 
NEOADJUANT CHEMOTHERAPY: 
TYPE OF REGIMEN: 
PATIENT DETAILS ON EACH CYCLE: 
    
    
 
SURGICAL TREATMENT 
TYPE OF SURGERY 
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HISTOPATHOLOGY 
 
 
 
 
POST-OPERATIVE CHEMOTHERAPY/ RADIOTHERAPY 
TYPE OF REGIMEN  
NO. OF CYCLES 
 
 
 
TYPE OF RT 
 
 
HORMONE THERAPY 
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FOLLOW UP 
RECURRENE IF ANY: 
ULCERATIONS 
LYMPH EDEMA 
SYMPTOMS OF METASTASIS 
RELEVANT INVESTIGATION 
DISEASE FREE INTERVAL. 
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PATIENT CONSENT FORM 
Study Title: A study on Locally Advanced Carcinoma of the Breast for a 
period of 2 years - regarding its management and prognosis 
STUDY CENTRE:  Department of General surgery, GMKMCH SALEM 
PARTICIPANT NAME:    AGE:  SEX:   
I.D. NO: 
I confirm that I have understood the purpose of surgical procedure for 
the above study. I have the opportunity to ask the question and all my questions 
and doubts have been answered to my satisfaction. 
I have been explained about the possible complications that may occur 
during surgical and post-surgical procedure. I understand that my participation 
in the study is voluntary and that I am free to withdraw at any time without 
giving any reason. 
I understand that investigator, regulatory authorities and the ethics 
committee will not need my permission to look at my health records both in 
respect to the current study and any further research that may be conducted in 
relation to it, even if I withdraw from the study. I understand that my identity 
will not be revealed in any information released to third parties or published, 
unless as required under the law. I agree not to restrict the use of any data or 
results that arise from the study. 
I hereby consent to participate in this study for various surgical 
procedures and their outcomes. 
Time: 
Date:     Signature / thumb impression of patient 
Place:     Patient’s Name: 
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MASTER 
CHART 
SL.  
NO NAME 
AGE/ 
SEX IP NO MENST
SIDE & 
QUADRANT TS STAGE CT[FAC] TS SURGERY HPE 
ER/PR/  
HER2-neu CT[FAC] RT RE/METS 
1 RATHINAM 45/F 49718 POST LUO 5 T3N2MO 3 2 MRM DCC  3 +  
2 CHINNATHAYEE 60/F 39154 POST RUO 7 T3N1MO 2 3 MRM DCC  4 +  
3 SHANTHI 41/F 70026 PRE LC 11 T4bN2MO 6 8 MRM+LDF DCC   + RE 
4 KANNAMMAL 47/F 75402  POST RUO 8 T3N1MO 3 4 MRM DCC  3 +  
5 KASTHURI 50/F 52947 POST RUO 12 T4bN3MO 3 5 MRM DCC  3   
6 MARIYAMMAL 43/f 25238 PRE LUO 6 T3N1MO 0  MRM DCC  6   
7 RANI 35/F 49561 PRE RUI 5 T3N1MO 2 3 MRM DCC NEG 4 + RE 
8 AMIRTHAVALLI 55/F 51856 POST RUO 6 T3N1MO 3 3 MRM DCC  3 +  
9 BANUMATHI 48/F 51914 POST RUO 8 T4bN2MO 3 3 MRM DCC  3 +  
10 SAMPOORNAM 60/F 53079 POST LUI 11 T3N1MO 3 6 MRM DCC  3 +  
11 PAPPATHI 55/F 74914 POST LUO 12 T4bN1MO 3 4 MRM DCC  3 +  
12 MAYAVATHY 65/F 78614 POST RUO 4 T2N1MO 0  MRM DCC  2   
13 PAPPA 45/F 78765 POST RUO 8 T4bN3MO 3 4 MRM DCC  3 + VERT METS 
14 VEERAMMAL 46/F 76889 POST RC 15 T4bN2MO 3 8 MRM DCC  3 +  
15 PAPPA 40/F 73860 PRE RUO 5 T3N1MO 3 3 MRM DCC  3 +  
16 LILLY 50/F 76335 POST RUO 8 T4bN1MO 3 5 MRM DCC  3 + LYMPHEDEMA 
17 SARADHAMMAL 55/F 76788 POST RUO 6 T3N1MO 3 4 MRM DCC NEG 3 +  
18 KASAMBAL 56/F 43079 POST RC 12 T4bN1MO 3 6 MRM DCC  3 +  
19 VIJAYA 60/F 31846 POST LUO 5 T3N1MO 3 3 MRM DCC  3 +  
20 DHANALAKSHMI 63/F 101777 POST LUO 8 T4CN2MO 6 5 MRM DCC   +  
21 MARIYAMMAL 45/F 92045 PRE LUO 6 T4bN1MO 2 3 MRM DCC ER/PR + 4 +  
22 SHANTHI 32/F 38035 PRE LUI 7 T4bN1MO 3 4 MRM DCC  3 + LYMPHEDEMA 
23 KAMALAM 63/F 92861 POST LUI 6 T3N1MO 3 4 MRM DCC  3 +  
24 PAPPU 55/F 31762 POST LUI 6 T3N1MO 3 3 MRM DCC  3 +  
25 VASANTHI 40/F 40024 PRE LUI 12 T4bN1MO 3 7 MRM DCC  3 + VERT METS 
26 CHINNAMMAL 50/F 106093 POST RUO 4 T2N1MO 2 2 MRM DCC  4 +  
27 SELVI 38/F 39536 PRE RLI 6 T3N1MO 3 3 MRM DCC  3 +  
28 CHANDRA 61/F 31762 POST RUO 6 T3N1MO 2 4 MRM DCC  4 + RE 
29 VASUKI 45/F 38762 PRE LC 10 T4bN1MO 3 6 MRM DCC  3 +  
30 BANUMATHI 42/F 77045 PRE LUO 10 T4bN1MO 3 5 MRM DCC  3 +  
31 SAROJA 58/F 105791 POST RUO 6 T4bN1MO 3 4 MRM DCC  3 + VERT METS 
32 ASHA 45/F 89865 PRE LUO 8 T4bN2MO 6 5 MRM DCC   +  
33 RANI 67/F 9628 POST LC 8 T3N1MO 3 4 MRM DCC  3 +  
34 BAKIYAM 55/F 106078 POST LUI 5 T4aN1MO 3 3 MRM DCC  3 +  
35 NIRMALA 36/F 34568 PRE LLI 5 T3N1MO 3 4 MRM DCC  3 +  
36 LAKSHMI 35/F 17056 PRE LUO 8 T4bN1MO 3 6 MRM DCC NEG 3 +  
37 REGINA 40/F 106305 PRE LC 7 T4bN1MO 3 5 MRM DCC     
38 MAHESWARI 58/F 41681 POST RUO 6 T3N1MO 2 3 MRM DCC  - -  
39 PADMAVATHI 27/f 58349 PRE RUO 8 T4bN1MO 3 4 MRM DCC  3 +  
40 JEYAKODI 38/F 25681 PRE RC 7 T4bN3MO 3 4 MRM DCC  3 +  
41 SANTHI 50/F 8819 POST RC 4 T3N1MO 2 3 MRM DCC  4 +  
42 VASANTHI 49/F 37532 POST RC 8 T4bN1MO 3 5 MRM DCC  3 +  
43 TAMILARASI 56/F 11107 POST LC 19 T4bN2MO 6 10 MRM DCC NEG - + LIVER METS 
44 MANORATHINAM 51/F 76946 POST RLI 5 T3N1MO 2 3 MRM DCC  4 + RE 
45 MALLIGA 38/F 77004 PRE RUO 5 T3N1MO 3 3 MRM DCC  3 +  
46 SHANTHI 33/F 82857 PRE RUO 8 T4bN1MO 3 4 MRM DCC  - -  
47 PERUMAYEE 48/F 72485 POST RUO 5 T3N1MO 2 4 MRM DCC  3 -  
48 TAMILARASI 36/F 82801 PRE LUI 6 T4bN1MO 3 4 MRM DCC  3 + VERT METS 
49 AMUDHA 45/F 73288 POST RUO 5 T4bN2MO 3 4 MRM DCC  - -  
50 BANU 47/F 74552 POST LUO 6 T3N1MO 3 4 MRM DCC  3 +  
51 SHANTHA 46/F 73287 POST RC 10 T4bN1MO 3 6 MRM DCC  3 + BRAIN METS 
52 LAKSHMI 60/F 109379 POST LUO 5 T3N1MO 2 2 MRM DCC  - -  
53 SULOCHANA 39/F 109783 PRE RUI 6 T3N1MO 3 3 MRM DCC  3 +  
54 DHANALAKSHMI 63/F 108885 POST RUO 12 T4bN1MO 3 7 MRM DCC  3 +  
55 MAHESWARI 43/F 6674 PRE LUO 6 T3N1MO 3 3 MRM DCC  3 +  
56 BAKIYAM 50/F 31752 POST LC 8 T4bN1MO 3 4 MRM DCC  3 +  
 57 KANAGAMANI 43/F 32425 POST LUO 5 T3N2MO 2 3 MRM DCC  2 +  
58 GANDHIMATHI 40/F 6357 PRE RUO 6 T3N1MO 3 4 MRM DCC  - -  
59 LAKSHMI 45/F 42425 POST LUO 10 T4bN2MO 3 5 MRM DCC  - -  
60 PAPPATHI 60/F 64863 POST RC 10 T4bN1MO 3 6 MRM DCC  3 +  
61 RAJATHI 43/F 60400 PRE RUI 8 T4bN2MO 3 5 MRM DCC  3 +  
62 CHELLAMMAL 45/F 94847 PRE RUO 4 T3N1MO 2 2 MRM DCC NEG 4 +  
63 KAMALAM 65/F 76890 POST RUO 6 T3N1MO 3 4 MRM DCC ER/PR+ 3 +  
64 SINDHAMANI 64/F 19075 POST LC 10 T4bN1MO 3 6 MRM DCC NEG 3 +  
65 BANUMATHY 40/F 9359 PRE LUI 6 T3N1MO 3 4 MRM DCC PR+/HER 2+    
66 KALIYAMMAL 68/F 83309 POST RUO 8 T3N1MO 3 6 MRM DCC ER+ 3 +  
67 GULZAR BEGUM 57/F 26896 POST RC 6 T3N1MO 3 5 MRM DCC HER2 +    
68 THANGAYEE 60/F 26507 POST RC 12 T4bN1MO 3 8 MRM DCC HER2 +    
69 KUPPAYEE 75/F 58632 POST RUO 8 T3N1MO 3 4 MRM DCC ER+ 3 +  
70 NALLAMMAL 60/F 73748 POST LUO 5 T3N1MO 3 4 MRM DCC  3 +  
MENST-Menstruation CT- Chemotherapy 
TS- Tumour stage HPE- Histo-pathological examination 
RE- Recurrence METS- Metastasis 
RUO- Right upper outer LUO- Left upper outer 
RUI- Right upper outer LUI- Left upper inner 
RC- Right central LC- Left central 
MRM- Modified radical mastectomy DCC- Ductal carcinoma in situ 
ER- Estrogen receptor PR- Progesterone receptor 
VERT- Vertebral   
